ADAM10: a new player in breast cancer progression?

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer

(2015) Katharina Feldinger et al.   Oncotarget

ADAM-17: a novel therapeutic target for triple negative breast cancer

(2012) P. M. McGowan et al.   ANNALS OF ONCOLOGY

Targeted therapy for triple-negative breast cancer: Where are we?

(2012) Michael J. Duffy et al.   INTERNATIONAL JOURNAL OF CANCER

The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling

(2011) S. Weber et al.   DEVELOPMENT

Cleavage of E-cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling

(2011) Guiomar Solanas et al.   NATURE CELL BIOLOGY

Role of ADAMs in Cancer Formation and Progression

(2009) M. J. Duffy et al.   CLINICAL CANCER RESEARCH

ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma

(2009) Sophia B. Lee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Selective Use of ADAM10 and ADAM17 in Activation of Notch1 Signaling

(2009) E. C. Bozkulak et al.   MOLECULAR AND CELLULAR BIOLOGY

ADAM10 as a Target for Anti-Cancer Therapy

(2008) Marcia Moss et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Fluorescent probes for super-resolution imaging in living cells

(2008) Marta Fernández-Suárez et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY